Recombinant oncolytic herpes simplex virus type 1 (R130)

DRUG5 trials

Sponsors

Shanghai Yunying Medical Technology

Conditions

Brain CancerBreast CancerBronchial CancerCarcinomaColorectal CancerDigestive CancerEar CancerEsophageal Cancer

Early Phase 1

A Clinical Study on Oncolytic Virus Injection (R130) for the Treatment of Relapsed/Refractory Ovarian Cancer

Shanghai Yunying Medical TechnologyFallopian Tube Cancer, Ovarian Cancer, Peritoneal Carcinomatosis

Start: 2022-12-02End: 2025-12-02Target: 10Updated: 2023-04-06

A Clinical Study on Oncolytic Virus Injection (R130 OV) for the Treatment of Relapsed/Refractory Head and Neck Cancer

RecruitingNCT05830240

Shanghai Yunying Medical TechnologyEar Cancer, Esophageal Cancer, Head and Neck Cancer +4

Start: 2023-03-27End: 2026-03-27Target: 9Updated: 2023-04-26

A Clinical Study on Oncolytic Virus Injection (R130) for the Treatment of Advanced Solid Tumors

RecruitingNCT05860374

Shanghai Yunying Medical TechnologyBreast Cancer, Carcinoma, Colorectal Cancer +6

Start: 2023-03-02End: 2026-03-02Target: 20Updated: 2023-05-16

A Clinical Study on Oncolytic Virus Injection (R130) for the Treatment of Relapsed/Refractory Advanced Solid Tumors

Shanghai Yunying Medical TechnologyBreast Cancer, Bronchial Cancer, Colorectal Cancer +9

Start: 2023-03-30End: 2025-03-31Target: 24Updated: 2023-06-02

A Clinical Study on Oncolytic Virus Injection (R130 OV) for the Treatment of Advanced Solid Tumors

RecruitingNCT05961111

Shanghai Yunying Medical TechnologyBrain Cancer, Breast Cancer, Carcinoma +7

Start: 2023-06-24End: 2026-06-30Target: 20Updated: 2023-07-27